Inventor · disambiguated record
Wayne C. Widdison
Also filed as: WIDDISON WAYNE · WIDDISON WAYNE C · WIDDISON WAYNE CHARLES
39 granted patents·10 pending applications·2,780 citations·filing 2000–2024
98Inventor score
Top patents by PatentIndex Score
49 records- 0199US7851432B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Dec 14, 2010·54 cites·33 claims
- 0299US7368565B2Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2002·Granted May 6, 2008·239 cites·17 claims
- 0399US7276497B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2004·Granted Oct 2, 2007·402 cites·31 claims
- 0499US6716821B2Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the sameIMMUNOGEN INC·Filed 2001·Granted Apr 6, 2004·359 cites·92 claims
- 0599US6441163B1Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agentsIMMUNOGEN INC·Filed 2001·Granted Aug 27, 2002·690 cites·27 claims
- 0699US6333410B1Process for the preparation and purification of thiol-containing maytansinoidsIMMUNOGEN INC·Filed 2000·Granted Dec 25, 2001·412 cites·34 claims
- 0798US7473796B2Cytotoxic agents comprising new maytansinoidsIMMUNOGEN INC·Filed 2007·Granted Jan 6, 2009·55 cites·13 claims
- 0898US7301019B2Method for the preparation of maytansinoid estersIMMUNOGEN INC·Filed 2006·Granted Nov 27, 2007·41 cites·27 claims
- 0998US6913748B2Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugsIMMUNOGEN INC·Filed 2003·Granted Jul 5, 2005·209 cites·34 claims
- 1097US8236319B2Cross-linkers and their usesCHARI RAVI V J·Filed 2009·Granted Aug 7, 2012·60 cites·15 claims
- 1197US7411063B2Process for preparation of maytansinolIMMUNOGEN INC·Filed 2006·Granted Aug 12, 2008·31 cites·48 claims
- 1295USRE39151EProcess for the preparation and purification of thiol-containing maytansinoidsIMMUNOGEN INC·Filed 2003·Granted Jun 27, 2006·72 cites·40 claims
- 1394US9061995B2Cross-linkers and their usesIMMUNOGEN INC·Filed 2013·Granted Jun 23, 2015·17 cites·33 claims
- 1494US8685920B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesCHARI RAVI V J·Filed 2011·Granted Apr 1, 2014·16 cites·37 claims
- 1594US8613930B2Cross-linkers and their usesCHARI RAVI V J·Filed 2012·Granted Dec 24, 2013·17 cites·26 claims
- 1694US8435528B2Cytotoxic agents comprising new maytansinoidsCHARI RAVI V J·Filed 2007·Granted May 7, 2013·20 cites·30 claims
- 1793US9498541B2Cross-linkers and their usesIMMUNOGEN INC·Filed 2015·Granted Nov 22, 2016·10 cites·21 claims
- 1893US8841425B2Cytotoxic agents comprising new maytansinoidsCHARI RAVI V J·Filed 2011·Granted Sep 23, 2014·7 cites·4 claims
- 1991US8563509B2Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesCHARI RAVI·Filed 2007·Granted Oct 22, 2013·18 cites·5 claims
- 2091US7432088B2Methods for the production of ansamitocinsIMMUNOGEN INC·Filed 2005·Granted Oct 7, 2008·15 cites·35 claims
- 2188US10792372B2Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereofIMMUNOGEN INC·Filed 2018·Granted Oct 6, 2020·2 cites·23 claims
- 2288US8388960B2Elimination of heterogeneous or mixed cell population in tumorsGOLDMAKHER VIKTOR S·Filed 2011·Granted Mar 5, 2013·7 cites·3 claims
- 2387US2025007192A1Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 2486US11229639B2Camptothecin derivativesIMMUNOGEN INC·Filed 2020·Granted Jan 25, 2022·1 cites·7 claims
- 2586US2024313444A1Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 2685US11135308B2Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereofIMMUNOGEN INC·Filed 2019·Granted Oct 5, 2021·1 cites·21 claims
- 2785US10461449B2Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2018·Granted Oct 29, 2019·1 cites·17 claims
- 2885US9090629B2Cytotoxic agents comprising new ansamitocin derivativesCHARI RAVI V J·Filed 2011·Granted Jul 28, 2015·10 cites·11 claims
- 2984US10494431B2Cross-linkers and their usesIMMUNOGEN INC·Filed 2018·Granted Dec 3, 2019·2 cites·8 claims
- 3084US10100062B2Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2017·Granted Oct 16, 2018·1 cites·20 claims
- 3184US9012629B2Methods for the acylation of maytansinolWIDDISON WAYNE C·Filed 2013·Granted Apr 21, 2015·2 cites·39 claims
- 3283US2024145953A1Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2023·Application pending·0 cites
- 3381US9999680B2Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agentsIMMUNOGEN INC·Filed 2014·Granted Jun 19, 2018·4 cites·5 claims
- 3478US9796731B2Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2016·Granted Oct 24, 2017·1 cites·13 claims
- 3577US9469655B2Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2015·Granted Oct 18, 2016·2 cites·22 claims
- 3676US11046762B2Cross-linkers and their usesIMMUNOGEN INC·Filed 2019·Granted Jun 29, 2021·0 cites·7 claims
- 3775US12390471B2Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereofIMMUNOGEN INC·Filed 2021·Granted Aug 19, 2025·0 cites·18 claims
- 3874US10944190B2Methods for the acylation of maytansinolIMMUNOGEN INC·Filed 2019·Granted Mar 9, 2021·0 cites·20 claims
- 3973US9289512B2Maytansinoid derivatives with peptide linker and conjugates thereofWIDDISON WAYNE C·Filed 2012·Granted Mar 22, 2016·2 cites·5 claims
- 4070US2018043013A1Cytotoxic agents comprising new maytansinoids (dm4)IMMUNOGEN INC·Filed 2017·Application pending·0 cites
- 4166US2022133711A1Camptothecin derivativesIMMUNOGEN INC·Filed 2021·Application pending·0 cites
- 4266US2015071949A1Cytotoxic agents comprising new maytansinoids (dm4)IMMUNOGEN INC·Filed 2014·Application pending·0 cites
- 4363US2012226025A1Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugatesCHARI RAVI V J·Filed 2012·Application pending·0 cites
- 4462US2017157264A1Cross-linkers and their usesIMMUNOGEN INC·Filed 2016·Application pending·0 cites
- 4555US9518017B2Purification of intermediates used in the preparation of heterobifunctional linkersIMMUNOGEN INC·Filed 2014·Granted Dec 13, 2016·0 cites·14 claims
- 4653US2023330240A1Technologies for preventing or treating infectionsBIOHAVEN THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4748US9901647B2Conjugates comprising cell-binding agents and cytotoxic agentsIMMUNOGEN INC·Filed 2014·Granted Feb 27, 2018·0 cites·4 claims
- 4847US10494423B2Maytansinoid derivatives with peptide linker and conjugates thereofIMMUNOGEN INC·Filed 2016·Granted Dec 3, 2019·0 cites·13 claims
- 4940US2016058882A1Cytotoxic agents comprising new ansamitocin derivativesIMMUNOGEN INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →